1. Home
  2. MBIO vs PRPO Comparison

MBIO vs PRPO Comparison

Compare MBIO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

BUY

Current Price

$0.46

Market Cap

4.1M

Sector

Health Care

ML Signal

BUY

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$23.77

Market Cap

42.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBIO
PRPO
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
42.0M
IPO Year
2023
2000

Fundamental Metrics

Financial Performance
Metric
MBIO
PRPO
Price
$0.46
$23.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.4K
★ 97.1K
Earning Date
11-06-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 98.99
92.15
EPS
★ N/A
N/A
Revenue
N/A
★ $24,049,000.00
Revenue This Year
N/A
$233.72
Revenue Next Year
$405.45
$22.61
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 29.77
52 Week Low
$0.46
$16.40
52 Week High
$1.84
$33.63

Technical Indicators

Market Signals
Indicator
MBIO
PRPO
Relative Strength Index (RSI) 33.39 42.16
Support Level N/A $23.75
Resistance Level $0.56 $24.95
Average True Range (ATR) 0.03 1.17
MACD -0.00 -0.35
Stochastic Oscillator 5.21 28.23

Price Performance

Historical Comparison
MBIO
PRPO

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About PRPO Precipio Inc.

Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

Share on Social Networks: